Immune Response and Modeled Duration of Protection Following a Single 60 μg Hepatitis B Vaccine Booster in Susceptible Chinese University Students
BACKGROUND: Since China incorporated the hepatitis B vaccine into its Expanded Program on Immunization (EPI) in 2002, the first cohort of infants to receive the full vaccination series has now reached college age. As vaccine-induced antibodies gradually wane, this cohort faces a higher risk of infection. Therefore, we assessed their current seroprotection status and evaluated the immunogenicity and short-term antibody kinetics of a single 60 μg booster dose in susceptible individuals, while also constructing a model of expected duration of protection. METHODS: In a multicenter study across three Anhui universities, 2988 students were screened for HBV markers. Among them, 160 who tested negative for all five markers received a single 60 μg booster. Antibody titers were monitored for 1-5 months. RESULTS: Serological screening showed 0.33% HBsAg positivity, 36.28% anti-HBs positivity, and 63.02% negativity for all markers, indicating high susceptibility. After the booster, seroprotection rate (SPR) remained >85% throughout follow-up, and anti-HBs geometric mean concentration (GMC) peaked at 1-2 months. Stratified analysis based on immune response status revealed that the proportion of high responders (≥100 mIU/mL) peaked early and then gradually declined, whereas the proportion of low responders (10-99.99 mIU/mL) increased over the follow-up period. A linear mixed-effects model predicted that protective levels (anti-HBs ≥10 mIU/mL) would persist for an average of 32.8 months. CONCLUSIONS: A substantial proportion of university students lack protective immunity against hepatitis B. A single 60 μg booster rapidly and effectively induced protection, demonstrating strong immunogenicity. These findings support implementing efficient booster strategies in university settings.
Authors
- Shaodi Ma (ORCID: https://orcid.org/0000-0003-1930-3936)
- BinBing Wang
- Shujie Zhou (ORCID: https://orcid.org/0009-0008-8309-7376)
- Ling Lin (ORCID: https://orcid.org/0000-0002-4029-4168)
- Leijing Mao
- Jihai Tang
- Yan Dong
- Haiyang Xu
- Feiyang Song
- Shouyan Geng
- Yuhui Cheng
- Mingxue Ren
- Xianwei Luo
- Pengcheng Miao
- Yu Chai
- Wenxiang Zhou
Institutions
- Bengbu Medical College (CN)
- Xian Center for Disease Control and Prevention (CN)
- Chuzhou University (CN)
- Anhui Provincial Center for Disease Control and Prevention (CN)
- Fuyang Second People's Hospital (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2026-04-14
- DOI
- https://doi.org/10.3390/vaccines14040345
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Foundation for Hepatitis Prevention and Control